JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for total ...

The company expects operating earnings (loss) between $(15) million and $10 million. Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced ...

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson's disease. The company plans to launch ONAPGO in the second quarter of 2025.

ONAPGO (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Supernus Pharmaceuticals received FDA approval for Onapgo, a drug/device combination product that continuously infuses the drug apomorphine to treat the “off” episodes experienced by Parkinson ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...